Discovery tool, not advice. Every figure is the published rule, not a decision on your case.

Grants

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

CARB-X funding solicitations

Status

Status not published

CARB-X issues periodic funding solicitations with themed topics; the most recent one referenced on the site is the 2024 solicitation. Deadlines are published per solicitation.

Check with the funder

Amount

Not published

Non-dilutive milestone-based awards for pre-clinical and early clinical antibacterial products. CARB-X has invested USD 506 million across 124 projects in 14 countries; individual awards have commonly ranged from a few hundred thousand to over USD 10 million including options.

Funder

CARB-X, hosted by Boston University

ppp · supranational

Deadline: annual_call — CARB-X issues periodic funding solicitations with themed topics; the most recent one referenced on the site is the 2024 solicitation. Deadlines are published per solicitation.

Your odds

Not published

This funder does not publish a success rate. We rank it using the rate observed across similar programmes and label it as an estimate rather than implying we know.

Effort

quick

Quick — mostly identity and bank details.

Who can apply

Sectors: health
Stage: pre_seed, seed, series_a
R&D activity required

Open to small companies, biotechs and academic spinouts worldwide working on antibiotics, preventatives (vaccines, microbiome), rapid diagnostics and other products against drug-resistant bacteria.

Apply on the funder's site

Source. https://carb-x.org/ — checked 2026-08-14

"new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria"